

eTable. Planned enrollment of post-marketing trials by industry and non-industry funding for indications targeted in trials.

Indication	Industry funding		Non-industry funding	
	No. of trials	Planned enrollment	No. of trials	Planned enrollment
<b>Originally approved indication</b>	2742	Median [Q1-Q3]: 100 [33-323] Mean (SD): 1322.0 (19921.8)	1251	Median [Q1-Q3]: 60 [29.5-150] Mean (SD): 230.9 (1771.2)
<b>Other indication(s)</b>	1310	Median [Q1-Q3]: 45 [24-128] Mean (SD): 167.7 (SD: 544.1)	1131	Median [Q1-Q3]: 40 [21-70] Mean (SD): 72.9 (148.0)
<b>Both the originally approved indication and another indication</b>	124	Median [Q1-Q3]: 60 [30-224] Mean (SD): 765.2 (2961.8)	121	Median [Q1-Q3]: 50 [30-120] Mean (SD): 218.1 (934.9)

Data were missing for 9 industry-funded trials and 5 other trials.